Red cell antigen genotyping Red cell antigen genotyping is a type of genetic testing offered through Canadian Blood Services at the National Immunohematology Reference Laboratory (NIRL). Available to healthcare providers across the country, this precise and comprehensive testing provides detailed information about specific antigens that may be present in a patient’s blood. Antigens may cause the immune system to produce antibodies, so understanding a patient’s unique combination of antigens is critical to selecting appropriate transfusion strategies. Patients who may benefit from red cell

For some patients who experience blood loss, transfusion with a blood product called albumin is often used to help restore their blood volume. However, albumin may not always be beneficial to the patients who receive it. Research that examines the evidence for appropriate use of blood products, like albumin, is important for both improving patient outcomes and for ensuring healthcare resources are used efficiently. That’s why Canadian Blood Services supports research programs like University of Toronto’s Quality in Utilization Education and Safety in Transfusion (QUEST), a research

A significant step In December 2021, Canadian Blood Services made a submission to Health Canada to focus donor screening criteria on higher-risk sexual behaviour, regardless of gender or sexuality, for all blood donors and all phlebotomy collection types. This is the latest and most significant step in a process that began over a decade ago, and that will continue to make participation in Canada’s Lifeline as minimally restrictive as possible, without compromising the safety of biological products or the adequacy of supply. Building the case for change Flashback to this month five years ago